Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
27 hedge funds and large institutions have $8.67M invested in Vincerx Pharma, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 18 closing their positions.
33% less funds holding
Funds holding: 40 → 27 (-13)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
72% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 18
80% less capital invested
Capital invested by funds: $42.8M → $8.67M (-$34.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$3.12M |
| 2 |
AC
Armistice Capital
New York
|
+$2.49M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$322K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$202K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$60.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$5.06M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$1.95M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$880K |
| 4 |
SCM
Sio Capital Management
New York
|
-$516K |
| 5 |
EP
Eversept Partners
New York
|
-$403K |
VINC Hedge Fund Activity: Q2 2024 in Review
27 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q2 2024, worth a combined $8.67M — down 80% from $42.8M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of VINC and 5 opened new positions — a net loss of 13 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Prosight Management, opening a new position worth an estimated $3.12M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $5.06M sold.
- 27 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q2 2024, down from 40 in Q1 2024.
- Funds reported $8.67M of Vincerx Pharma, Inc. Common Stock stock for Q2 2024, down 80% quarter-over-quarter.
- 5 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q2 2024 and 18 closed out, a net change of -13 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q2 2024 was Prosight Management, an estimated $3.12M added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q2 2024 was Octagon Capital Advisors, an estimated $5.06M sold.
Based on aggregated 13F filings for Q2 2024.